Pharvaris (NASDAQ:PHVS - Get Free Report) was down 11.7% during mid-day trading on Monday . The stock traded as low as $15.57 and last traded at $15.71. Approximately 7,724 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 42,822 shares. The stock had previously closed at $17.80.
Pharvaris Trading Down 7.8 %
The company has a market cap of $522.49 million, a price-to-earnings ratio of -5.86 and a beta of -3.06. The business has a 50-day moving average price of $19.97 and a 200 day moving average price of $19.34.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris in the 3rd quarter valued at about $57,000. Barclays PLC purchased a new stake in Pharvaris in the 3rd quarter worth approximately $106,000. HighVista Strategies LLC boosted its stake in shares of Pharvaris by 35.9% during the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock valued at $422,000 after buying an additional 6,018 shares during the period. Jane Street Group LLC purchased a new position in shares of Pharvaris during the 3rd quarter valued at $526,000. Finally, Geode Capital Management LLC increased its stake in shares of Pharvaris by 18.4% in the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock worth $685,000 after acquiring an additional 5,753 shares during the last quarter.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
